Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 23Unspecified Adult Solid Tumor, Protocol Specific 14Urinary Bladder Neoplasms 13Ovarian Neoplasms 12Fallopian Tube Neoplasms 9Lymphoma, Large B-Cell, Diffuse 6Hodgkin Disease 6Breast Neoplasms 6Adenocarcinoma of Lung 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Lymphoma, Follicular 5Carcinoma, Ovarian Epithelial 5Burkitt Lymphoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Colorectal Neoplasms 4Colonic Neoplasms 4Urethral Neoplasms 3Ureteral Neoplasms 3Sezary Syndrome 3Rectal Neoplasms 3Nasopharyngeal Neoplasms 3

Interventions

adavosertib 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic Pancreatic Adenocarcinoma × Gemcitabine × Clear all
NCT02194829 2023-04-25

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Completed
8 enrolled 9 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡